Experimental vaccine displays potential in type 1 diabetes

06/27/2013 | Reuters

Insulin-treated type 1 diabetes patients who received the experimental vaccine TOL-3021 once weekly showed increased C-peptide levels and attained reductions in T-cell rates, according to a study in Science Translational Medicine. The vaccine also helped preserve some remaining beta cells in patients at 12 weeks without side effects, researchers noted.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA